$PLXP News

Last published 3y ago

3y agoPLXPPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its AssetsGlobeNewswireSPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and
3y agoPLXPPLx Pharma Inc. Receives Nasdaq Delisting NoticeGlobeNewswireSPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and
4y agoPLXPPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business UpdateGlobeNewswire- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and
4y agoPLXPPLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business UpdateGlobeNewswireSPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and
4y agoPLXPApproval of Vazalore, Nda #203697 (Manufacturing (CMC))FDA Approved DrugsApproval Date: 10/03/2022; Drug Name: Vazalore, Nda #203697; Active Ingredients: ASPIRIN; Company: Plx Pharma; Submission Status: Approval; Submission Classification: Manufacturing (CMC); Application Number: 203697
4y agoPLXPBaseball Legend John Smoltz Featured on PLx Pharma's Social ChannelsGlobeNewswireSPARTA, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po
4y agoPLXPSurvey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mgGlobeNewswireResults of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE)
4y agoPLXPPLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business UpdateGlobeNewswire- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million
4y agoPLXPPLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business UpdateGlobeNewswireSPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po
4y agoPLXPPLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022GlobeNewswireSPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po
4y agoPLXPPLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and InterventionsGlobeNewswireSPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po
4y agoPLXPPLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business UpdateGlobeNewswireBUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-G
4y agoPLXPPLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business UpdateGlobeNewswireSPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the p
4y agoPLXPPLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business UpdateGlobeNewswireMomentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021 Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sal
4y agoPLXPPLx Pharma Inc. to Present at Oppenheimer & Co's 32nd Annual Healthcare Conference on March 15, 2022GlobeNewswireSPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the p
4y agoPLXPPLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business UpdateGlobeNewswireSPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po
4y agoPLXPPLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health AwarenessGlobeNewswire-- Female-Led Company Strives to Transform Standard of Care in Secondary Prevention of Heart Attack or Clot-Related Stroke with its Innovative New Aspirin Formulation VAZALORE® -- SPARTA, N. J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc.
4y agoPLXPPLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate CommunicationsGlobeNewswireSPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po
4y agoPLXPPLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021GlobeNewswireSPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the pot
4y agoPLXPApproval of Vazalore, Nda #203697 (Labeling)FDA Approved DrugsApproval Date: 11/16/2021; Drug Name: Vazalore, Nda #203697; Active Ingredients: ASPIRIN; Company: Plx Pharma; Submission Status: Approval; Submission Classification: Labeling; Application Number: 203697
5y agoPLXPPLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business UpdateGlobeNewswire-- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of
5y agoPLXPPLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin CapsulesGlobeNewswire-- VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition -- -- VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent withVAZALORE 325 mg -- -- Findings presented at TCT meeting earlier today -- SPART
5y agoPLXPPLx Pharma Inc. to Discuss 2021 Third Quarter Financial Results on November 12, 2021 Conference Call and Provide Business UpdateGlobeNewswireSPARTA, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the poten
5y agoPLXPPLx Pharma Inc. Provides VAZALORE Launch UpdateGlobeNewswire-- Supplied VAZALORE to 30,000+ stores nationwide and e-commerce sites -- -- Launch in line with expectations and exceptionally positive feedback from consumers and healthcare professionals received -- -- Third quarter 2021 earnings and busines
5y agoPLXPPLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx's VAZALORE Specifically Indicated for Secondary PreventionGlobeNewswireSPARTA, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoPLXPRandomized, Crossover Bioequivalence Study of PL-ASA vs Immediate-release Aspirin in Healthy Volunteers. - NCT05055752ClinicalTrials.govBioequivalence of single-dose acetylsalicylic acid PK of the PL-ASA formulation to IR-ASA in healthy volunteers at 325 mg dose level.
5y agoPLXPPLx Pharma Inc. to Present at Upcoming Virtual Healthcare Industry ConferencesGlobeNewswireSPARTA, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effe
5y agoPLXPPLx Pharma Inc.'s VAZALORE™ Now on Shelves; National Media Campaign Launches TodayGlobeNewswire-- Executing broad reach television advertising to support the launch of VAZALORE -- -- Media campaign reach matches extensive distribution at retailers -- SPARTA, N.J., Aug. 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or th
5y agoPLXPPLx Pharma Inc. Reports Second Quarter 2021 Results and Provides Business UpdateGlobeNewswire--Walmart, Walgreens, Rite Aid, CVS and many other retailers placing VAZALORE on shelves later this month-- --VAZALORE launch inventory manufactured and currently shipping to retailers across the country-- SPARTA, N.J., Aug. 06, 2021 (GLOBE NEWSW
5y agoPLXPPLx Pharma Inc.'s VAZALORE to Launch in Nearly 8,000 CVS Stores this MonthGlobeNewswireSPARTA, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoPLXPPLx Pharma Inc.'s VAZALORE to Launch in Over 2,400 Rite Aid Stores in AugustGlobeNewswireSPARTA, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoPLXPPLx Pharma Inc. to Discuss 2021 Second Quarter Financial Results on August 6, 2021 Conference Call and Provide Business UpdateGlobeNewswireSPARTA, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoAMRX NRBO OEG PLXP+1Thinking about buying stock in Neurobo Pharmaceuticals, Xenetic Biosciences, Amneal Pharmaceuticals, PLx Pharma, or Orbital Energy Group?PR NewswireNEW YORK, July 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRBO, XBIO, AMRX, PLXP, and OEG. T
5y agoPLXPPLx Pharma Inc.'s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in AugustGlobeNewswireSPARTA, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoPLXPPLx Pharma Inc.'s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in AugustGlobeNewswireSPARTA, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoPLXPPLx Pharma Inc. to Present at Upcoming Healthcare Industry ConferencesGlobeNewswireSPARTA, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effec
5y agoCVGI PLXP SCPS VSTM+1Thinking about buying stock in Scopus Biopharma, Verastem, Vistagen, PLx Pharma, or Commercial Vehicle?PR NewswireNEW YORK, May 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SCPS, VSTM, VTGN, PLXP, and CVGI. To
5y agoPLXPPLx Pharma Inc. Reports First Quarter 2021 Results and Provides Business UpdateGlobeNewswire– VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsules, gain FDA approval – – Company secured $71.4 million of gross proceeds in an underwritten public offering of common stock for the launch of VAZALORE – –
5y agoPLXPPLx Pharma, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 14, 2021 / PLx Pharma, Inc. (NASDAQ:PLXP) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 14, 2021 at 8:30 AM Eastern Time. To listen to the event live or access a rep
5y agoPLXPPLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business UpdateGlobeNewswireSPARTA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide mo
5y agoPLXPPharmacodynamic and Pharmacokinetic Study of PL-ASA - NCT04811625ClinicalTrials.govSerum thromboxane B2, Acetylsalicylic acid and salicylic acid
5y agoPLXPPLx Pharma Inc. Reports Fourth Quarter and Full Year 2020 Results and Provides Business UpdateGlobeNewswire-- Received FDA approval of sNDAs for both VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsule -- -- U.S. commercial launch of VAZALORE planned for third quarter...
5y agoPLXPPLx Pharma Inc. to Present at the Oppenheimer 31st Annual Healthcare ConferenceGlobeNewswireSPARTA, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected...
5y agoPLXPPLx Pharma Inc. to Discuss 2020 Fourth Quarter Financial Results on March 12, 2021 Conference Call and Provide Business UpdateGlobeNewswireSPARTA, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and...
5y agoPLXPPLx Pharma Inc. Prices $63 Million Underwritten Public Offering of Common StockGlobeNewswireSPARTA, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and...
5y agoPLXPPLx Pharma Inc. Announces Proposed Public Offering of Common StockGlobeNewswireSPARTA, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and...
5y agoPLXPPLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mgGlobeNewswire-- VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications – --...
5y agoPLXPPLx Pharma Inc. Reports Third Quarter 2020 Results and Provides Business UpdateGlobeNewswire--Announces $18 million private placement-- --Submitted sNDAs for VAZALORE 325 mg and 81 mg doses to FDA end of October-- --On target for third quarter 2021 commercial launch of VAZALORE-- SPARTA,...
5y agoPLXPPLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug AdministrationGlobeNewswire-- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 – SPARTA, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- PLx Pharma...
6y agoPLXPPLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020GlobeNewswireSPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated...